◎ Sugi Atlas

Atlas / Drug / Dopamine

Dopamine

drug
On this page

Also known as A-dopamineDobutamine aDopaminaMedopaNSC-173182OxytyramineSID11111282SID26750067SID26753787SID90341661SID104171172SID124880336SID124880337SID26753786SID50107800SID57288369SID144203718SID124880340SID170464942

Summary

Dopamine (CHEMBL59) is an approved small-molecule cardiotonic drug (ATC C01CA04) targeting DRD1, DRD2, and DRD3; indicated across 10 conditions including cardiovascular disorder and toxic shock syndrome.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: C01CA04
  • Targets: 5 (DRD1, DRD2, DRD3…)
  • Indications: 10 conditions
  • Clinical trials: 38
  • Chemistry: 153.18 Da · C8H11NO2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL59
NameDopamine
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID681
ChEBICHEBI:18243
ATCC01CA04
Molecular formulaC8H11NO2
Molecular weight153.18
InChIKeyVYFYYTLLBUKUHU-UHFFFAOYSA-N

SMILES: C1=CC(=C(C=C1CCN)O)O

IUPAC name: 4-(2-aminoethyl)benzene-1,2-diol

ChEBI definition: Catechol in which the hydrogen at position 4 is substituted by a 2-aminoethyl group.

Pharmacological roles (ChEBI): cardiotonic drug, β-adrenergic agonist, dopaminergic agent, sympathomimetic agent.

Other ChEBI roles (chemical / environmental): human metabolite, Escherichia coli metabolite, mouse metabolite.

Also known as: A-dopamine, Dobutamine a, Dopamina, Dopamine, Medopa, NSC-173182, Oxytyramine, dopamine, SID11111282, SID26750067, SID26753787, SID90341661

Parent form; salt/anhydrous children: CHEMBL1557, CHEMBL3247442

Patent coverage: 77,754 distinct patent families (217,028 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 216,801 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
DRD1D1 receptorFull agonist5.60%P21728
DRD2D2 receptorFull agonist7.20%P14416
DRD3D3 receptorFull agonist7.30%P35462
DRD4D4 receptorFull agonist7.60%P21917
DRD5D5 receptorFull agonist6.60%P21918

Broader ChEMBL bioactivity targets: 53 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, ATP-dependent DNA helicase Q1, 4’-phosphopantetheinyl transferase ffp, Thrombopoietin, Solute carrier family 22 member 3, D(1B) dopamine receptor, Alpha-2A adrenergic receptor.

Bioactivity

ChEMBL activities: 284 potent at pChembl ≥ 5 of 312 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
DRD39.96EC500.11nMCHEMBL_ACT_19268341
DRD39.4AC500.4nMCHEMBL_ACT_25193503
DRD29.17EC500.67nMCHEMBL_ACT_18043275
DRD39.17EC500.68nMCHEMBL_ACT_25621900
DRD39.17EC500.68nMCHEMBL_ACT_25621901
DRD29.16EC500.69nMCHEMBL_ACT_16819970
DRD29.11EC500.78nMCHEMBL_ACT_18043306
DRD29.1EC500.8nMCHEMBL_ACT_19451757
DRD39.05EC500.89nMCHEMBL_ACT_24412139
DRD29EC500.99nMCHEMBL_ACT_18985531
P611698.96EC501.1nMCHEMBL_ACT_1796534
DRD38.96EC501.1nMCHEMBL_ACT_19270531
P611698.96EC501.1nMCHEMBL_ACT_790870
DRD48.92Ki1.2nMCHEMBL_ACT_570801
DRD38.8EC501.6nMCHEMBL_ACT_25513385
DRD38.74EC501.8nMCHEMBL_ACT_13317543
DRD38.74EC501.8nMCHEMBL_ACT_16566465
DRD48.74EC501.8nMCHEMBL_ACT_19451766
P202888.74Ki1.8nMCHEMBL_ACT_570804
DRD28.72Ki1.89nMCHEMBL_ACT_334380
DRD28.72Ki1.89nMCHEMBL_ACT_419017
DRD58.7EC502nMCHEMBL_ACT_19451775
P189018.7IC502nMCHEMBL_ACT_549694
DRD38.68EC502.1nMCHEMBL_ACT_18813970
P189018.68IC502.1nMCHEMBL_ACT_549695
DRD48.66EC502.2nMCHEMBL_ACT_1796525
DRD48.66EC502.2nMCHEMBL_ACT_790865
DRD38.64EC502.3nMCHEMBL_ACT_19270528
P307298.62EC502.4nMCHEMBL_ACT_1796531
P307298.62EC502.4nMCHEMBL_ACT_790867

Target pathways

Aggregated over 5 target gene(s): DRD1, DRD2, DRD3, DRD4, DRD5.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Dopamine receptors5DRD1, DRD2, DRD3, DRD4, DRD5
G alpha (s) signalling events2DRD1, DRD5
G alpha (i) signalling events2DRD3, DRD4

Dominant GO biological processes

GO termTargets
phospholipase C-activating dopamine receptor signaling pathway5
synaptic transmission, dopaminergic5
signal transduction5
G protein-coupled receptor signaling pathway5
response to amphetamine4
behavioral response to cocaine4
response to cocaine4
intracellular calcium ion homeostasis4
adenylate cyclase-activating dopamine receptor signaling pathway3
G protein-coupled dopamine receptor signaling pathway3
visual learning3
response to xenobiotic stimulus3
dopamine metabolic process3
positive regulation of MAPK cascade3
regulation of dopamine uptake involved in synaptic transmission3

Indications & clinical

Indications

10 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
cardiovascular disorder4MONDO:0004995EFO:0000319
toxic shock syndrome3MONDO:0001881EFO:0006834
congenital heart disease3MONDO:0005453EFO:0005207
Parkinson disease3MONDO:0005180MONDO:0005180
heart failure2MONDO:0005252EFO:0003144
diabetes mellitus1MONDO:0005015EFO:0000400
depressive disorder1MONDO:0002050MONDO:0002050

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 38.

Phase distribution

PhaseTrials
Not specified14
PHASE411
PHASE14
PHASE33
PHASE2/PHASE32
PHASE22
PHASE1/PHASE22

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07322133PHASE4RECRUITINGDopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)
NCT00126087PHASE4TERMINATEDPotentiation of Procedural Motor Learning in Health and Disease
NCT00484133PHASE4UNKNOWNMicrocirculation Guided Therapy Versus Standard Treatment of Severe Sepsis
NCT01140399PHASE4TERMINATEDREWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure
NCT01427686PHASE4UNKNOWNDopamine Versus Dobutamine for Treatment of Arterial Hypotension in Term and Preterm Neonates
NCT01901809PHASE4COMPLETEDDiuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
NCT02241083PHASE4COMPLETEDThe Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements
NCT03151460PHASE4COMPLETEDDopaminergic Modulation of Declarative Memory
NCT03170739PHASE4UNKNOWNEffects of Dexmedetomidine and Dopamine on Renal Function After Major Surgery
NCT03892447PHASE4UNKNOWNThe Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury
NCT04107480PHASE4UNKNOWNPRolaCT - Three Prolactinoma RCTs
NCT04750070PHASE3RECRUITINGManagement of Shock in Children With SAM or Severe Underweight and Diarrhea
NCT00604019PHASE3COMPLETEDDopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock
NCT02428062PHASE2/PHASE3SUSPENDEDTarget Hemodynamics and Brain Injury During General Anesthesia in the Elderly
NCT03107858PHASE2/PHASE3UNKNOWNThe Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function
NCT04536194PHASE3COMPLETEDDopamine Versus Norepinephrine Under General Anesthesia
NCT01132846PHASE2COMPLETEDRenal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study
NCT04332276PHASE1/PHASE2COMPLETEDDopaminergic restauratIon by intraVEntriculaire Administration
NCT04525495PHASE2UNKNOWNDopamine in Neonate
NCT07214285PHASE1/PHASE2COMPLETEDEvaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)
NCT00874393PHASE1COMPLETEDEarly Blood Pressure Management in Extremely Premature Infants
NCT02009007PHASE1UNKNOWNVasopressors for Cerebral Oxygenation
NCT02053935PHASE1COMPLETEDImpact of Dopamine Infusion on Insulin Secretion in Healthy Subjects
NCT06611423PHASE1TERMINATEDAZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
NCT03778944Not specifiedRECRUITINGEnhancing Renal Graft Function During Donor Anesthesia
NCT05347238Not specifiedRECRUITINGDopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis
NCT05732077Not specifiedRECRUITINGFractional Flow Reserve to Determine Atherosclerosis Renovascular Hypertension Stenting
NCT06447740Not specifiedRECRUITINGFractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis
NCT07111442Not specifiedNOT_YET_RECRUITINGA Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients
NCT07273526Not specifiedRECRUITINGAdrenaline V/s Dopamine in Fuid Refractory Septic Shock
NCT07562932Not specifiedNOT_YET_RECRUITINGAssessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock
NCT01318278Not specifiedCOMPLETEDStudy of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants
NCT01722630Not specifiedCOMPLETEDRenal Function During Laparoscopic Surgery
NCT02726620Not specifiedCOMPLETEDDecision Support for Intraoperative Low Blood Pressure
NCT02921282Not specifiedCOMPLETEDNicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms
NCT02965963Not specifiedCOMPLETEDThe Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise
NCT03780686Not specifiedCOMPLETEDDopamine and Norepinephrine Infusion With Restricted Hydration
NCT04753008Not specifiedUNKNOWNRespiratory Effects of Dopamine in the Perioperative Care

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

597 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CLOZAPINEChEMBL + PubChemPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
DIHYDROERGOTAMINEChEMBL + PubChemPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
OLANZAPINEChEMBL + PubChemPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
PALIPERIDONEChEMBL + PubChemPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
PramipexoleChEMBL + PubChemPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
AMITRIPTYLINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
AMOXAPINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
APOMORPHINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
ARIPIPRAZOLEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
BREXPIPRAZOLEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
CABERGOLINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
CARIPRAZINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
CHLORPROMAZINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
DOXEPINChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
FLUPHENAZINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
HALOPERIDOLChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
IMIPRAMINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
LOXAPINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
PROMAZINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
RISPERIDONEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
ROPINIROLEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
TEGASERODChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4, DRD5
PENFLURIDOLChEMBLPhase 2DRD1, DRD2, DRD3, DRD4, DRD5
RACLOPRIDEChEMBLPhase 2DRD1, DRD2, DRD3, DRD4, DRD5
RITANSERINChEMBLPhase 2DRD1, DRD2, DRD3, DRD4, DRD5
DESLORATADINEChEMBL + PubChemPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
AMIODARONEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
ASENAPINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
ASTEMIZOLEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
BENPERIDOLChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
BROMOCRIPTINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
CARVEDILOLChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
CHLORPROTHIXENEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD5
CLOTRIMAZOLEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
DISULFIRAMChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
DOBUTAMINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
EBASTINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
ECONAZOLEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
ILOPERIDONEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
KETANSERINChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
KETOTIFENChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD5
LOPERAMIDEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
MAPROTILINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD5
MECLIZINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
MIANSERINChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
MICONAZOLEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
NEFAZODONEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
PERGOLIDEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
PIMOZIDEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
PROCHLORPERAZINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
PROMETHAZINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
QUETIAPINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
ROTIGOTINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
SERTINDOLEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
SILODOSINChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
SULPIRIDEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
SUNITINIBChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
TAMOXIFENChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
THIORIDAZINEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4
THIOTHIXENEChEMBLPhase 4 (approved)DRD1, DRD2, DRD3, DRD4

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot